Online inquiry

IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4714MR)

This product GTTS-WQ4714MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets MAPT gene. The antibody can be applied in Progressive supranuclear palsy (PSP) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001123066.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4137
UniProt ID P10636
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ4714MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12925MR IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PankoMab
GTTS-WQ11445MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEDI-9447
GTTS-WQ14649MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ1908MR IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AGN 150998
GTTS-WQ12834MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ONC-005
GTTS-WQ9896MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA KB001-A
GTTS-WQ5345MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ4330MR IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BIVV009
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW